Does the media prefer SION or QGEN?

In the previous week, Qiagen had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Qiagen and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.48 beat Qiagen's score of -0.41 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, PCVX or SION?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A

Is PCVX or SION more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Sionna Therapeutics N/A -27.31% -25.88%

Does the media favor PCVX or SION?

In the previous week, Vaxcyte had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.48 beat Vaxcyte's score of 0.21 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sionna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SION or IMVT?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is SION or IMVT more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -27.31% -25.88% Immunovant N/A -65.66% -59.88%

Does the media prefer SION or IMVT?

In the previous week, Immunovant had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for Immunovant and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.48 beat Immunovant's score of 0.43 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SION or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than Sionna Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Sionna Therapeutics. Kymera Therapeutics' average media sentiment score of 1.39 beat Sionna Therapeutics' score of 0.48 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SION or PTGX?

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Sionna Therapeutics. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 3 mentions for Sionna Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.72 beat Sionna Therapeutics' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sionna Therapeutics (SION) Competitors

$37.78 +1.08 (+2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$37.84 +0.06 (+0.17%)

As of 07:07 PM Eastern

Compare

SION vs. QGEN, PCVX, IMVT, KYMR, and PTGX

Should you buy Sionna Therapeutics stock or one of its competitors? MarketBeat compares Sionna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sionna Therapeutics include Qiagen (QGEN), Vaxcyte (PCVX), Immunovant (IMVT), Kymera Therapeutics (KYMR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Sionna Therapeutics compare to Qiagen?

Sionna Therapeutics (NASDAQ:SION) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Qiagen has a net margin of 19.16% compared to Sionna Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Qiagen	19.16%	14.40%	8.40%

Sionna Therapeutics currently has a consensus target price of $53.22, indicating a potential upside of 40.87%. Qiagen has a consensus target price of $44.98, indicating a potential upside of 19.92%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sionna Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

In the previous week, Qiagen had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Qiagen and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.48 beat Qiagen's score of -0.41 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.0% of Qiagen shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Qiagen has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Qiagen	$2.09B	3.70	$424.88M	$1.91	19.64

Sionna Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

Qiagen beats Sionna Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sionna Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

96.8% of Vaxcyte shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vaxcyte has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

In the previous week, Vaxcyte had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.48 beat Vaxcyte's score of 0.21 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 76.37%. Sionna Therapeutics has a consensus target price of $53.22, indicating a potential upside of 40.87%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Sionna Therapeutics' return on equity of -27.31% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Summary

Sionna Therapeutics beats Vaxcyte on 10 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Immunovant?

Sionna Therapeutics (NASDAQ:SION) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

In the previous week, Immunovant had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for Immunovant and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.48 beat Immunovant's score of 0.43 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sionna Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Sionna Therapeutics currently has a consensus price target of $53.22, suggesting a potential upside of 40.87%. Immunovant has a consensus price target of $37.33, suggesting a potential upside of 14.27%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sionna Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

47.1% of Immunovant shares are held by institutional investors. 5.1% of Sionna Therapeutics shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sionna Therapeutics' return on equity of -27.31% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Immunovant	N/A	-65.66%	-59.88%

Summary

Sionna Therapeutics beats Immunovant on 11 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Kymera Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Sionna Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Kymera Therapeutics	$39.21M	156.53	-$311.35M	-$3.57	N/A

Sionna Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 1 more articles in the media than Sionna Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Sionna Therapeutics. Kymera Therapeutics' average media sentiment score of 1.39 beat Sionna Therapeutics' score of 0.48 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics presently has a consensus price target of $53.22, suggesting a potential upside of 40.87%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 58.28%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Sionna Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Summary

Kymera Therapeutics beats Sionna Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Protagonist Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Sionna Therapeutics has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Protagonist Therapeutics	$46.02M	143.64	-$130.15M	-$1.81	N/A

Sionna Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Sionna Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Sionna Therapeutics. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 3 mentions for Sionna Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.72 beat Sionna Therapeutics' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics currently has a consensus target price of $53.22, suggesting a potential upside of 40.87%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 12.09%. Given Sionna Therapeutics' higher probable upside, research analysts clearly believe Sionna Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Sionna Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Sionna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SION vs. The Competition

Export

Metric	Sionna Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.66B	$3.28B	$6.30B	$12.43B
Dividend Yield	N/A	2.36%	2.69%	5.33%
P/E Ratio	-19.58	18.46	24.03	24.35
Price / Sales	N/A	326.03	523.15	115.20
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	5.49	6.77	9.98	6.72
Net Income	-$75.27M	$24.09M	$3.56B	$337.03M
7 Day Performance	-11.73%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	139.11%	48.90%	28.76%	33.98%

Sionna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SION Sionna Therapeutics	2.6684 of 5 stars	$37.78 +2.9%	$53.22 +40.9%	+153.5%	$1.66B	N/A	N/A	35
QGEN Qiagen	4.0143 of 5 stars	$36.65 +1.5%	$44.98 +22.7%	-23.5%	$7.45B	$2.09B	19.14	5,654
PCVX Vaxcyte	2.7673 of 5 stars	$51.06 +0.1%	$86.00 +68.4%	+35.4%	$7.37B	N/A	N/A	160	Insider Trade
IMVT Immunovant	2.07 of 5 stars	$33.50 +0.3%	$37.33 +11.4%	+101.7%	$6.86B	N/A	N/A	120
KYMR Kymera Therapeutics	2.4221 of 5 stars	$81.46 -0.3%	$118.10 +45.0%	+67.9%	$6.72B	$39.21M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SION) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sionna Therapeutics (SION) Competitors

SION vs. QGEN, PCVX, IMVT, KYMR, and PTGX

How does Sionna Therapeutics compare to Qiagen?

Summary

How does Sionna Therapeutics compare to Vaxcyte?

Summary

How does Sionna Therapeutics compare to Immunovant?

Summary

How does Sionna Therapeutics compare to Kymera Therapeutics?

Summary

How does Sionna Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sionna Therapeutics (SION) Competitors

SION vs. QGEN, PCVX, IMVT, KYMR, and PTGX

How does Sionna Therapeutics compare to Qiagen?

Is SION or QGEN more profitable?

Do analysts recommend SION or QGEN?

Does the media prefer SION or QGEN?

Do insiders & institutionals believe in SION or QGEN?

Which has higher valuation & earnings, SION or QGEN?

Which has more volatility and risk, SION or QGEN?

Summary

How does Sionna Therapeutics compare to Vaxcyte?

Do institutionals & insiders believe in PCVX or SION?

Which has more volatility and risk, PCVX or SION?

Does the media favor PCVX or SION?

Do analysts rate PCVX or SION?

Is PCVX or SION more profitable?

Which has better valuation & earnings, PCVX or SION?

Summary

How does Sionna Therapeutics compare to Immunovant?

Does the media prefer SION or IMVT?

Which has more volatility and risk, SION or IMVT?

Do analysts recommend SION or IMVT?

Which has higher valuation & earnings, SION or IMVT?

Do institutionals & insiders have more ownership in SION or IMVT?

Is SION or IMVT more profitable?

Summary

How does Sionna Therapeutics compare to Kymera Therapeutics?

Which has better valuation and earnings, SION or KYMR?

Is SION or KYMR more profitable?

Does the media refer more to SION or KYMR?

Do analysts recommend SION or KYMR?

Which has more volatility and risk, SION or KYMR?

Summary

How does Sionna Therapeutics compare to Protagonist Therapeutics?

Which has preferable earnings & valuation, SION or PTGX?

Which has more volatility and risk, SION or PTGX?

Is SION or PTGX more profitable?

Does the media refer more to SION or PTGX?

Do analysts rate SION or PTGX?

Do insiders and institutionals hold more shares of SION or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools